A phase 1 study of AstraZeneca’s investigational monoclonal antibody AZD7442 for the prevention and treatment of coronavirus disease 2019 (COVID-19) has been initiated.
AZD7442 is a combination of 2 monoclonal antibodies derived from convalescent patients who were infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The monoclonal antibodies have been optimized with an extended half-life to afford at least 6 months of protection from COVID-19. According to preclinical data recently published in Nature, the monoclonal antibodies protect against infection by blocking SARS-CoV-2 virus from binding to host cells.
“This combination of antibodies, coupled to our proprietary half-life extension technology, has the potential to improve both the effectiveness and durability of use in addition to reducing the likelihood of viral resistance,” said Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca.
The randomized, double-blind, placebo-controlled phase 1 study will evaluate the safety, tolerability, and pharmacokinetics of AZD7442 in up to 48 healthy participants aged 18 to 55 years. The study is funded by the Defense Advanced Research Projects Agency (DARPA) and the Biomedical Advanced Research and Development Authority (BARDA) at the US Department of Health and Human Services.
The Company expects to present study data in the second half of 2020.
For more information visit astrazeneca.com.
Phase I clinical trial initiated for monoclonal antibody combination for the prevention and treatment of COVID-19. https://www.astrazeneca.com/media-centre/press-releases/2020/phase-1-clinical-trial-initiated-for-monoclonal-antibody-combination-for-the-prevention-and-treatment-of-covid-19.html. Accessed August 25, 2020.
This article originally appeared on MPR